Celltrion, Inc. (068270.KS)

183,400.00 +800.00 (+0.44%) At close: 03:30PM KST

Celltrion, Inc.

23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Hyong-Gi Kim	CEO & Internal Director	N/A	N/A	1965
Mr. Woo-Sung Kee	CEO & Internal Director	N/A	N/A	1961
Jin-seok Seo	Co-CEO & Inside Co-Chairman of the Board	N/A	N/A	N/A
Mr. Stephen Yeum	Founder	N/A	N/A	N/A
Mr. Min-Cheol Shin	Director of Finance	N/A	N/A	1971
Mr. Ji-Hoon Choi	Director of Legal Affairs	N/A	N/A	1971

Amounts are as of 31 December 2011, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Corporate governance

Celltrion, Inc.’s ISS governance QualityScore as of 1 June 2024 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 4; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.